ClinicalTrials.gg
CompletedNCT00754507Updated Apr 3, 2015

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.

A Phase 4 interventional study of colesevelam HCl tablets, and atorvastatin tablets and colesevelam HCl placebo tablets and atorvastatin tablets in Hypercholesterolemia, sponsored by Daiichi Sankyo. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-03.

Sponsored by Daiichi Sankyo · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hypercholesterolemia by Daiichi Sankyo — 1 open to participants now, 2 under way, 1 of them phase 3. Hypercholesterolemia · Daiichi Sankyo.

Started
2002
with 2 others
Phase 4
6 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Hypercholesterolemia by Daiichi Sankyo, this one is one of 3 that started in 2002, is one of 6 in phase 4, and was the 5th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 12 studies in Hypercholesterolemia by Daiichi Sankyo is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypercholesterolemia by Daiichi Sankyo, or all of them as a file.
02

Study summary

To determine the effects of WelChol tablets on serum lipids, lipoproteins, apolipoproteins, and lipoprotein particle size in patients who were stabilized on atorvastatin therapy for at least 4 weeks.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female > or greater than 18 years of age
  • On a stable dose of atorvastatin
  • LDL-C > or = to 115 mg/dL and \< or = to 250 mg/dL
  • TG \< or = to 300 mg/dL
  • Women are not pregnant or breast-feeding or planning to become pregnant
  • Women of had a hysterectomy or tubal-ligation, or
  • women were post menopausal, or
  • women practiced an acceptable method of as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  • > 40 kg/m2
  • History of allergic or toxic reaction to colesevelam HCl
  • History of swallowing disorders
  • Any serious disorder that could impact the conduct of the study
  • History of drug or alcohol abuse
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    1

    colesevelam tablets and atorvastatin tablets

    Drug: colesevelam HCl tablets, and atorvastatin tablets

  • Placebo comparator
    2

    colesevelam HCl placebo tablets and atorvastatin tablets

    Drug: colesevelam HCl placebo tablets and atorvastatin tablets

Interventions

  • Drugcolesevelam HCl tablets, and atorvastatin tablets

    colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks

  • Drugcolesevelam HCl placebo tablets and atorvastatin tablets

    colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks

06

What researchers measure

Primary outcomes

  1. The primary efficacy parameter is the percent change in LDL-C from baseline to endpoint.

    Time frame: 6 weeks

Secondary outcomes

  1. The absolute change in LDL-C from baseline to endpoint

    Time frame: 6 weeks

  2. The absolute change and % change in total cholesterol

    Time frame: 6 Weeks

  3. The absolute change and % change in triglycerides

    Time frame: 6 Weeks

  4. The absolute change and % change in HDL-C

    Time frame: 6 Weeks

  5. The absolute change and % change in C-reactive protein

    Time frame: 6 weeks

07

Study locations

13 sites
  • Los Angeles, California, United States
  • Castle Rock, Colorado, United States
  • Jacksonville, Florida, United States
  • Pembroke Pines, Florida, United States
  • St. Petersburg, Florida, United States
  • Indianapolis, Indiana, United States
  • Rochester, New York, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Bartlett, Tennessee, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Jun 2003 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2008
First posted
Sep 18, 2008
Start
Nov 2002
Primary completionActual
Jun 2003
CompletionActual
Apr 2005
Last update
Apr 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00754507
Lead sponsor
Daiichi Sankyo
First posted
Sep 18, 2008
Start date
Nov 2002
Primary completion
Jun 2003
Completion
Apr 2005
Last update
Apr 3, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion